Kaitlin Forsberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kaitlin Forsberg has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Meghan Lyman
Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia
4 shared publications - Brendan R. Jackson
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
2 shared publications - Shawn R. Lockhart
Mycotic Diseases Branch, Centers for Disease Control and Prevention
2 shared publications Anastasia P. Litvintseva
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta , GA
1 shared publication- Ansley Waters
Department of Epidemiology, Milken School of Public Health, George Washington University, Washington, District of Columbia, USA
1 shared publication Brenda L Nguyen
Division of Violence Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication
Latest Publications
- 15 October 2026
- Published by BMJ in Injury Prevention
Stalking-related homicides in the USA, National Violent Death Reporting System, 2012–2022
Background Stalking, a pattern of harassing or threatening behaviour against another person causing fear or concern for personal safety, can have severe consequences, including homicide. This study describes the characteristics of the USA stalking-related homicides and compares them to non-stalking-related homicides. Methods We examined stalking-related compared with non-stalking-related homicide data from 2012 to 2022 using the National Violent Death Reporting System and a multidimensional stalking assessment and safety planning framework. Results From 2012 to 2022, 593 stalking-related homicides and 145 409 non-stalking-related homicides were identified. Intimate partners were the stalking perpetrator for 83.5% of stalking-related homicides. Stalking-related homicides had higher odds of female decedents than non-stalking homicides. Most decedents were stalking victims (60.4%); fewer were stalking perpetrators (20.6%) or corollary victims of stalking (19.1%). Stalking victim decedents were largely female (87.4%), while corollary stalking victims and stalking perpetrator decedents were mostly male (78.8%; 97.5%). A recent or impending relationship separation was present for 74.5% of decedents. Law enforcement was aware of the stalking through reporting to law enforcement in 35.9% of cases including restraining orders against the perpetrators (16.5%). Common stalking tactics reported were surveillance (87.9%); intimidation (60.2%), like threats of physical harm (46.7%) and sabotage/attack tactics (32.9%), especially physical sabotage/attacks (27.5%). Conclusions Stalking-related homicides were highly related to intimate partner violence, particularly around times of relationship separation. Strategies for preventing intimate partner violence and related homicide could include promoting healthy relationship skills, engaging key adults and peers, ensuring safe environments and supporting families and victims.
- 15 October 2026
- Published by BMJ in Injury Prevention
Stalking-related homicides in the USA, National Violent Death Reporting System, 2012–2022
Background Stalking, a pattern of harassing or threatening behaviour against another person causing fear or concern for personal safety, can have severe consequences, including homicide. This study describes the characteristics of the USA stalking-related homicides and compares them to non-stalking-related homicides. Methods We examined stalking-related compared with non-stalking-related homicide data from 2012 to 2022 using the National Violent Death Reporting System and a multidimensional stalking assessment and safety planning framework. Results From 2012 to 2022, 593 stalking-related homicides and 145 409 non-stalking-related homicides were identified. Intimate partners were the stalking perpetrator for 83.5% of stalking-related homicides. Stalking-related homicides had higher odds of female decedents than non-stalking homicides. Most decedents were stalking victims (60.4%); fewer were stalking perpetrators (20.6%) or corollary victims of stalking (19.1%). Stalking victim decedents were largely female (87.4%), while corollary stalking victims and stalking perpetrator decedents were mostly male (78.8%; 97.5%). A recent or impending relationship separation was present for 74.5% of decedents. Law enforcement was aware of the stalking through reporting to law enforcement in 35.9% of cases including restraining orders against the perpetrators (16.5%). Common stalking tactics reported were surveillance (87.9%); intimidation (60.2%), like threats of physical harm (46.7%) and sabotage/attack tactics (32.9%), especially physical sabotage/attacks (27.5%). Conclusions Stalking-related homicides were highly related to intimate partner violence, particularly around times of relationship separation. Strategies for preventing intimate partner violence and related homicide could include promoting healthy relationship skills, engaging key adults and peers, ensuring safe environments and supporting families and victims.
- 2 April 2026
- Vol. 116 (6) , e1-e12
Racial/Ethnic Differences in Homicides of Adult Women and the Role of Intimate Partner Violence: United States, 2018-2022.
Objectives. To describe rates and characteristics of homicides of women across racial/ethnic groups, and describe intimate partner violence (IPV)-related and non-IPV-related homicide circumstances across racial/ethnic groups. Methods. We used National Vital Statistics System data to calculate homicide rates by racial/ethnic group of US women (aged ≥ 18 years) who were homicide victims from 2018 to 2022. We used National Violent Death Reporting System data to characterize the circumstances and suspects in these homicides by racial/ethnic group and IPV involvement. Results. The age-adjusted homicide rate was 3.2 per 100 000 women. Rates for non-Hispanic Black women and non-Hispanic American Indian/Alaska Native women were more than twice as high as those for other races/ethnicities. Most women were killed by a firearm (67.9%), fatally injured in a residence (64.8%), or killed by a male (92.5%). About half (47.3%) of homicides were IPV related. Non-IPV-related homicides were often perpetrated by family members (39.0%). Circumstances differed by racial/ethnic group. Conclusions. Homicide disproportionally affects certain racial/ethnic groups of women, and the characteristics of homicides differ across groups. Thorough examination of these differences could aid in effective, targeted homicide prevention. (Am J Public Health. Published online ahead of print April 2, 2026:e1-e12. https://doi.org/10.2105/AJPH.2026.308461).
- 2 April 2026
- Vol. 116 (6) , e1-e12
Racial/Ethnic Differences in Homicides of Adult Women and the Role of Intimate Partner Violence: United States, 2018-2022.
Objectives. To describe rates and characteristics of homicides of women across racial/ethnic groups, and describe intimate partner violence (IPV)-related and non-IPV-related homicide circumstances across racial/ethnic groups. Methods. We used National Vital Statistics System data to calculate homicide rates by racial/ethnic group of US women (aged ≥ 18 years) who were homicide victims from 2018 to 2022. We used National Violent Death Reporting System data to characterize the circumstances and suspects in these homicides by racial/ethnic group and IPV involvement. Results. The age-adjusted homicide rate was 3.2 per 100 000 women. Rates for non-Hispanic Black women and non-Hispanic American Indian/Alaska Native women were more than twice as high as those for other races/ethnicities. Most women were killed by a firearm (67.9%), fatally injured in a residence (64.8%), or killed by a male (92.5%). About half (47.3%) of homicides were IPV related. Non-IPV-related homicides were often perpetrated by family members (39.0%). Circumstances differed by racial/ethnic group. Conclusions. Homicide disproportionally affects certain racial/ethnic groups of women, and the characteristics of homicides differ across groups. Thorough examination of these differences could aid in effective, targeted homicide prevention. (Am J Public Health. Published online ahead of print April 2, 2026:e1-e12. https://doi.org/10.2105/AJPH.2026.308461).
- 7 March 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (6) , 766-769
Candida auris screening practices at healthcare facilities in the United States: An Emerging Infections Network survey
We surveyed members of the Emerging Infections Network about Candida auris screening practices at US healthcare facilities. Only 37% of respondents reported conducting screening; among these, 75% reported detection of at least 1 C. auris case in the last year. Increased screening could improve C. auris detection and prevent spread.
- 7 March 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (6) , 766-769
Candida auris screening practices at healthcare facilities in the United States: An Emerging Infections Network survey
We surveyed members of the Emerging Infections Network about Candida auris screening practices at US healthcare facilities. Only 37% of respondents reported conducting screening; among these, 75% reported detection of at least 1 C. auris case in the last year. Increased screening could improve C. auris detection and prevent spread.
- Top Cited Papers
- 1 April 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (4) , 489-495
Worsening Spread of Candida auris in the United States, 2019 to 2021
Candida auris is an emerging fungal threat that has been spreading in the United States since it was first reported in 2016. To describe recent changes in the U.S. epidemiology of C auris occurring from 2019 to 2021. Description of national surveillance data. United States. Persons with any specimen that was positive for C auris. Case counts reported to the Centers for Disease Control and Prevention by health departments, volume of colonization screening, and antifungal susceptibility results were aggregated and compared over time and by geographic region. A total of 3270 clinical cases and 7413 screening cases of C auris were reported in the United States through 31 December 2021. The percentage increase in clinical cases grew each year, from a 44% increase in 2019 to a 95% increase in 2021. Colonization screening volume and screening cases increased in 2021 by more than 80% and more than 200%, respectively. From 2019 to 2021, 17 states identified their first C auris case. The number of C auris cases that were resistant to echinocandins in 2021 was about 3 times that in each of the previous 2 years. Identification of screening cases depends on screening that is done on the basis of need and available resources. Screening is not conducted uniformly across the United States, so the true burden of C auris cases may be underestimated. C auris cases and transmission have risen in recent years, with a dramatic increase in 2021. The rise in echinocandin-resistant cases and evidence of transmission is particularly concerning because echinocandins are first-line therapy for invasive Candida infections, including C auris. These findings highlight the need for improved detection and infection control practices to prevent spread of C auris. None.
- 1 April 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (4) , 489-495
Top Cited PapersWorsening Spread of Candida auris in the United States, 2019 to 2021
Candida auris is an emerging fungal threat that has been spreading in the United States since it was first reported in 2016. To describe recent changes in the U.S. epidemiology of C auris occurring from 2019 to 2021. Description of national surveillance data. United States. Persons with any specimen that was positive for C auris. Case counts reported to the Centers for Disease Control and Prevention by health departments, volume of colonization screening, and antifungal susceptibility results were aggregated and compared over time and by geographic region. A total of 3270 clinical cases and 7413 screening cases of C auris were reported in the United States through 31 December 2021. The percentage increase in clinical cases grew each year, from a 44% increase in 2019 to a 95% increase in 2021. Colonization screening volume and screening cases increased in 2021 by more than 80% and more than 200%, respectively. From 2019 to 2021, 17 states identified their first C auris case. The number of C auris cases that were resistant to echinocandins in 2021 was about 3 times that in each of the previous 2 years. Identification of screening cases depends on screening that is done on the basis of need and available resources. Screening is not conducted uniformly across the United States, so the true burden of C auris cases may be underestimated. C auris cases and transmission have risen in recent years, with a dramatic increase in 2021. The rise in echinocandin-resistant cases and evidence of transmission is particularly concerning because echinocandins are first-line therapy for invasive Candida infections, including C auris. These findings highlight the need for improved detection and infection control practices to prevent spread of C auris. None.
- 16 December 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 51 (4) , 472-474
Investigation of a Candida auris outbreak in a skilled nursing facility — Virginia, United States, October 2020–June 2021
- 16 December 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 51 (4) , 472-474
Investigation of a Candida auris outbreak in a skilled nursing facility — Virginia, United States, October 2020–June 2021
- Open Access
- 1 October 2020
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (Supplement) , S206-S207
155. Public Health Action-based System for Tracking and Responding to U.S. candida Drug Resistance: AR Lab Network, 2016–2019
Many U.S. clinical laboratories lack capacity to definitively identify fungi or perform antifungal susceptibility testing (AFST). To expand testing access, CDC’s Antibiotic Resistance Laboratory Network (AR Lab Network) provides Candida species identification and AFST to U.S. facilities for clinical and public health purposes. We describe the first three years of Candida AR Lab Network resistance data. Isolates from any body site with species identification and AFST performed July 2016–June 2019 are included. Submissions were based on clinical and public health need. Patients may have multiple isolates. The 7 AR Lab Network regional laboratories used matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) or DNA sequencing for species identification. AFST was performed using broth microdilution for azoles and echinocandins (anidulafungin and micafungin) and Etest for amphotericin B. This analysis focuses on non-albicans Candida species with Clinical and Laboratory Standards Institute M60 minimum inhibitory concentration breakpoints and C. auris, which has CDC-proposed tentative breakpoints. Participation increased from healthcare facilities from 2 states submitting in 2016 to 35 states in 2019. Species identification was performed on 5,234 non-albicans isolates. AFST was performed on 4,222 (81%) isolates, including 2,395 C. glabrata, 815 C. auris, 267 C. parapsilosis, 125 C. tropicalis, 35 C. guilliermondii, and 32 C. krusei. Of isolates with AFST and body site indicated, 22% (900/4,102) were from blood. We found 85% of C. auris, 8% of C. glabrata, and 5% of C. parapsilosis isolates were resistant to azoles; 33% of C. auris isolates were resistant to amphotericin B; and 2% of C. glabrata, 1% of C. auris, and 1% of C. parapsilosis isolates were resistant to echinocandins. Although intrinsically resistant to fluconazole, C. krusei isolates were not resistant to voriconazole. Multidrug resistance was present in 32% of C. auris and 1% of C. glabrata isolates. AR Lab Network has expanded access to rapid Candida testing, including AFST, and provides real-time surveillance. Results can be used to detect emerging species and resistance and guide public health action and healthcare practices. All Authors: No reported disclosures
- 1 October 2020
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (Supplement) , S206-S207
Open Access155. Public Health Action-based System for Tracking and Responding to U.S. candida Drug Resistance: AR Lab Network, 2016–2019
Many U.S. clinical laboratories lack capacity to definitively identify fungi or perform antifungal susceptibility testing (AFST). To expand testing access, CDC’s Antibiotic Resistance Laboratory Network (AR Lab Network) provides Candida species identification and AFST to U.S. facilities for clinical and public health purposes. We describe the first three years of Candida AR Lab Network resistance data. Isolates from any body site with species identification and AFST performed July 2016–June 2019 are included. Submissions were based on clinical and public health need. Patients may have multiple isolates. The 7 AR Lab Network regional laboratories used matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) or DNA sequencing for species identification. AFST was performed using broth microdilution for azoles and echinocandins (anidulafungin and micafungin) and Etest for amphotericin B. This analysis focuses on non-albicans Candida species with Clinical and Laboratory Standards Institute M60 minimum inhibitory concentration breakpoints and C. auris, which has CDC-proposed tentative breakpoints. Participation increased from healthcare facilities from 2 states submitting in 2016 to 35 states in 2019. Species identification was performed on 5,234 non-albicans isolates. AFST was performed on 4,222 (81%) isolates, including 2,395 C. glabrata, 815 C. auris, 267 C. parapsilosis, 125 C. tropicalis, 35 C. guilliermondii, and 32 C. krusei. Of isolates with AFST and body site indicated, 22% (900/4,102) were from blood. We found 85% of C. auris, 8% of C. glabrata, and 5% of C. parapsilosis isolates were resistant to azoles; 33% of C. auris isolates were resistant to amphotericin B; and 2% of C. glabrata, 1% of C. auris, and 1% of C. parapsilosis isolates were resistant to echinocandins. Although intrinsically resistant to fluconazole, C. krusei isolates were not resistant to voriconazole. Multidrug resistance was present in 32% of C. auris and 1% of C. glabrata isolates. AR Lab Network has expanded access to rapid Candida testing, including AFST, and provides real-time surveillance. Results can be used to detect emerging species and resistance and guide public health action and healthcare practices. All Authors: No reported disclosures